Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals
Portfolio Pulse from Vandana Singh
Erasca Inc (NASDAQ:ERAS) is discontinuing certain pipeline programs due to lack of clinical activity and will focus on programs with encouraging activity signals. The company will deprioritize ERAS-9, ERAS-11, and ERAS-2/3, but continue pursuing other research approaches to target RAS mutations. Preliminary Phase 1b data for ERAS-007 in patients with metastatic BRAF V600E-mutated colorectal cancer showed a 50% response rate at the highest dose.
June 06, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Erasca is discontinuing certain pipeline programs and focusing on promising research approaches targeting RAS mutations. Preliminary Phase 1b data for ERAS-007 showed a 50% response rate.
Erasca's decision to discontinue certain pipeline programs and focus on more promising research approaches may have a neutral short-term impact on its stock price. While discontinuing programs may be seen as a setback, the preliminary Phase 1b data for ERAS-007 showing a 50% response rate could be viewed as a positive development.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100